Evaluation of Periodontal Health, Salivary Cotinine and S100A8/A9 Levels in Children Exposed to Passive Smoking
Launched by CUMHURIYET UNIVERSITY · Jan 20, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how being around cigarette smoke affects the gum health of children. Researchers want to understand the levels of certain proteins in saliva that may show inflammation caused by exposure to secondhand smoke. The trial will focus on children who are healthy and not taking any medications that could interfere with their immune system or dental health.
To participate, children must be between 6 to 12 years old and should not have any orthodontic devices, like braces, or be on certain medications. The trial is not currently recruiting participants, but once it starts, children who qualify will have their gum health and saliva analyzed to help us learn more about the impact of secondhand smoke. This study aims to provide important information that could help improve the health of children exposed to smoke in their environment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Systemically and genetically healthy children
- Exclusion Criteria:
- • Any medications known to affect defense system and periodontium
- • The presence of orthodontic / intraoral appliance
About Cumhuriyet University
Cumhuriyet University is a distinguished academic institution located in Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive resources and expertise to facilitate innovative studies that aim to enhance healthcare outcomes. With a focus on interdisciplinary collaboration, Cumhuriyet University fosters an environment conducive to rigorous scientific inquiry and ethical research practices, ensuring that trials conducted under its auspices adhere to the highest standards of quality and integrity. Through its dedicated efforts, the university contributes significantly to the global body of medical knowledge and the development of effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sivas, , Turkey
Patients applied
Trial Officials
Arzu Koçkanat, Asst.Prof.
Study Chair
Cumhuriyet University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported